Monoclonal antibodies for treating infectious diseases;Anticorps thérapeutiques et maladies infectieuses

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1116-1120

  Klinguer Hamour, Christine ^a   Caussanel, Véronique ^a   Beck, Alain ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749095881     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121116     Document Type: Review

References (15)

1. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007 ; 25:1421-34.
2. Ledford H. Monoclonal antibodies come of age. Nature 2008 ; 455:437.
3. Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009 ; 69: 31-50.
4. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 ; 11: 615-22.
5. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 ; 449:101-4.
6. Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6:143-55.
7. Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006 ; 5:191-5.
8. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007;4:el78.
9. Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008 ; 455:532-6.
10. Mansbach J, Kunz S, Acholonu U, et al. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 2007; 23: 362-7.
11. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007 ; 368 : 652-5.
12. De Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007 ; 58 : 359-68.
13. Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008 ; 14 : 1357-62.
14. Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007 ; 21 : 1-7.
15. Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005 ; 11 : 522-30.